FDA denies approval for Actavis hypertension treatment

By

Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

The company said it would review the U.S. Food and Drug Administration's complete response letter and decide on appropriate next steps.

The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form.

Actavis did not give any further details on the contents of the letter.

In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension, compared with independent doses of nebivolol and valsartan, Actavis said.

The company's shares closed at $254.20 on the New York Stock Exchange on Wednesday.

Tags
U.S., U.S. Food and Drug Administration
Join the Discussion
More News
Why Did Kohberger Spare Roommates in Idaho Murders?

Everything We Know About Shane Tamura, Who Pleaded For Experts to 'Study' His Brain After Killing Several in NYC Office Shooting

Who is Eliotte Heinz: Missing Wisconsin Grad Student Found Dead

Suspects In Viral Cincinnati Street Brawl Identified As Police Chief Slams Bystanders For Not Intervening: 'Out of 100, Only 1 Called 911'

Amy Bradley Is Missing

Kim Kardashian Joins 25-Year Search For Amy Bradley After 'Mind Blowing' Netflix Doc Shocks Viewers

Wisconsin Woman Reveals How She Dismembered Boyfriend, Spread Body Parts

Wisconsin Woman Details How She Dismembered Boyfriend, Spread Body Parts Around House in Disturbing Jailhouse Call